

# SUPPLEMENTARY DATA

## Section 1. Literature search

---

### Literature search in MEDLINE

---

**Research period** 2007/01/01 - 2017/12/31

---

**Indexing terms** acquired resistance, adjuvant chemotherapy, adjuvant platinum-based chemotherapy, advanced disease, advanced ovarian cancer, advanced stage, antiangiogenic therapy, appendectomy, appendiceal involvement, ATP-binding cassette, ATP copper transporters, bevacizumab, bilateral cystectomy, biomarker, biopsy, borderline ovarian tumor, cancer antigen 125, carboplatin, carcinoma, cediranib, cell-free DNA, chemoresistance, chemotherapy resistance, circulating biomarker, circulating tumor cells, circulating tumor DNA, cisplatin, clear cell, clinical marker, conservative approach, conservative surgical procedure, conservative surgical treatment, conservative treatment, conventional chemotherapy, conventional regimens, conventional therapy, contralateral cystectomy, chemotherapy response score, chemotherapy response score system, computed tomography, cystectomy, diagnostic laparoscopy, dose-dense chemotherapy, dose-dense regimens, dose-dense therapy, duration of treatment, early disease, early stage, expansile invasion, expansile subtype, extraovarian implant, fertility sparing, fertility sparing surgery, first-line treatment, follow-up, follow-up strategy, frozen section analysis, genomic factor, high grade, high grade serous carcinoma, high risk, histological factor, histological type, homologous recombination, hormonal therapy maintenance, hormone treatment, human epididymis protein 4, hyperthermic intraperitoneal chemotherapy, imaging, immune checkpoint inhibitors, implant, infiltrative invasion, infiltrative subtype, institutional infrastructure, intermediate risk, interval debulking surgery, intraperitoneal chemotherapy, intrinsic resistance, invasive implant, invasive ovarian cancer, invasive ovarian neoplasia, laboratory marker, low grade serous carcinoma, liquid biopsy, loss of heterozygosity, low grade, low risk, lymphadenectomy, lymph node metastases, maintenance, maintenance therapy, maintenance treatment, marker, membrane transporters, micropapillary architecture, molecularly targeted therapy, monitoring, mucinous, magnetic resonance imaging, neoadjuvant chemotherapy, niraparib, non-homologous recombination, non-high grade, non-serous, olaparib, ovarian cancer, ovarian carcinoma, paclitaxel, poly-(ADP-ribose) polymerase inhibitors, poly-(ADP-ribose) polymerase inhibitor therapy, poly-(ADP-ribose) polymerase inhibitor treatment, peritoneal staging surgery, positron emission tomography/computed tomography, progression-free interval, physical examination, physician experience, physician specialization, platinum-based chemotherapy, platinum resistance, platinum-resistant disease, platinum-resistant recurrent ovarian cancer, platinum response, platinum-sensitive recurrence, platinum-sensitive recurrent ovarian cancer, platinum sensitivity, primary debulking surgery, quaternary cytoreduction, quaternary cytoreductive surgery, radical approach, radical surgical procedure, radical surgical treatment, radical surgery, recurrence, recurrent disease, recurrent ovarian cancer, refractory disease, relapse, response, restaging, restaging procedure, restaging surgery, routine biopsy, routine surveillance, routine surveillance testing, rucaparib, secondary cytoreduction, secondary cytoreductive surgery, selection criteria, serous, single nucleotide variant signature, solute carrier, stage, surgery, surgical management, surgical treatment, surveillance, systemic treatment, tertiary cytoreduction, tertiary cytoreductive surgery, targeted therapy, time of platinum therapy, tissue biomarker, trabectedin, treatment response, trebananib, tumor biomarkers, tumor grade, tumor involvement, unilateral cystectomy, unilateral salpingo-oophorectomy, vismodegib, weekly regimen, whole-genome sequencing

---

**Language** English

---

**Study design** Priority was given to high-quality systematic reviews and meta-analyses but lower levels of evidence were also evaluated. The search strategy excluded editorials, letters, case reports and *in vitro* studies

---